Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s goals for 2030
The weight-loss-drug manufacturer failed to excite investors hoping for a turnaround.
The weight-loss-drug manufacturer failed to excite investors hoping for a turnaround. This story matters for Finance & Markets readers tracking fund. Reported by marketwatch.com. Read the full original at the source link below.
Originally reported by marketwatch.com. FundNews curates and briefs the finance & markets stories that matter. Our editorial policy →